JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer

Phase 3Not Yet RecruitingNCT07823348

Shanghai Junshi Bioscience Co., Ltd.560 enrolled

Overview

This is a multicenter, randomized, open-label, controlled Phase III clinical study designed to evaluate the efficacy and safety of JS207 in combination with JS007 versus toripalimab in combination with bevacizumab as first-line treatment in participants with advanced HCC. All study participants have unresectable locally advanced, recurrent, or metastatic HCC and have not previously received systemic anti-tumor therapy for advanced disease. Approximately 560 participants are planned to be enrolled in this study. The JS207 + JS007 group (experimental group) and the toripalimab + bevacizumab group (positive control group) are each planned to enroll 280 participants.

This is a multicenter, randomized, open-label, active-controlled Phase III study in participants with unresectable locally advanced, recurrent, or metastatic hepatocellular carcinoma.Tumor images will be assessed by investigator and blinded independent central review (BICR). Treatment will continue until protocol-defined discontinuation criteria are met, for a maximum of 2 years. Participants will undergo tumor assessments, safety assessments, and survival follow-up. Anti-tumor activity will be assessed by determining best overall response (BOR), objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (BICR-PFS and INV Safety will be assessed through AEs, laboratory variables, physical examination findings, vital signs, 12-lead electrocardiogram, echocardiography, and ECOG performance status. The severity of AEs will be graded per NCI-CTCAE v6.0. Participants in the JS207 + JS007 group (experimental group) will undergo plasma concentration assessments and immunogenicity assessments for JS207 and JS007. The EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D-5L questionnaires will be used to assess participants' health-related quality of life (HRQOL).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Interventions

JS207DRUG

PD-1/VEGF bispecific antibody supplied as a lyophilized powder for intravenous infusion.

JS007DRUG

CTLA-4 monoclonal antibody supplied as an injectable solution for intravenous infusion.

ToripalimabDRUG

PD-1 monoclonal antibody supplied as an injectable solution for intravenous infusion.

BevacizumabDRUG

VEGF monoclonal antibody supplied as an injectable solution for intravenous infusion.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Voluntarily participate and sign a written informed consent form. * Aged 18-75 years, regardless of sex. * Histologically/cytologically confirmed HCC, or cirrhosis meeting the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria for HCC. * No prior systemic therapy for HCC. * At least one measurable lesion per RECIST v1.1 criteria. * Child-Pugh liver function grade A or grade B with a score ≤7, and no history of hepatic encephalopathy. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1. * Expected survival ≥ 12 weeks. * Adequate hematologic and end-organ function. * Female participants of childbearing potential and male participants with female partners of childbearing potential must use a highly effective contraceptive method during the study and for at least 6 months after the last dose. Female participants of childbearing potential must have a negative blood HCG test within 7 days prior to study enrollment and must not be breastfeeding. Exclusion Criteria: * Concomitant with the following study disease states: Known intrahepatic cholangiocarcinoma (ICC) or mixed-type liver cancer, sarcomatoid hepatocellular carcinoma, and fibrolamellar carcinoma of the liver; Presence of HCC central nervous system metastasis. * Prior treatment-related toxicity not recovered to ≤ CTCAE Grade 1. * Severe infection at screening. * Uncontrolled pericardial effusion, uncontrolled pleural effusion, or clinically apparent moderate or greater ascites at screening. -≥ Grade 3 (NCI-CTCAE v6.0) gastrointestinal or non-gastrointestinal fistula at screening. * Severe unhealed wounds, active ulcers, or untreated fractures at screening. * Severe cardiovascular or cerebrovascular disease: * History of gastrointestinal bleeding within 6 months prior to the first dose, or definite tendency for gastrointestinal bleeding. * Other obvious bleeding tendency or evidence of major coagulation disorders: * Active autoimmune disease requiring systemic treatment within 2 years prior to the first dose. * Malignancy other than HCC within 5 years prior to the first dose. * Confirmed or suspected moderate-to-severe pulmonary disease severely affecting pulmonary function. * Active tuberculosis. * Co-infection with hepatitis B and hepatitis C. * Known history of human immunodeficiency virus (HIV) infection, prior allogeneic stem cell or solid organ transplantation, or other immunodeficiency. * Known history of severe allergy to any monoclonal antibody. * Other factors that, in the investigator's judgment, may affect study results or lead to forced premature termination of the study.

Outcomes

Primary Outcomes

Progression-Free Survival Assessed by Blinded Independent Central Review (BICR-PFS)

Time from randomization to the first documented disease progression assessed by BICR per RECIST v1.1 or death from any cause, whichever occurs first. Tumor assessments use Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Assessments are performed every 6 weeks through Week 54 and every 9 weeks thereafter.

Time frame: From randomization to disease progression or death, whichever occurs first; assessed up to 24 months.

Overall Survival (OS)

Time from randomization to death from any cause. After safety follow-up, survival status is assessed every 2 months until death, loss to follow-up, withdrawal of consent, or study termination.

Time frame: From randomization to death from any cause; assessed up to 66 months.

Secondary Outcomes

Progression-Free Survival Assessed by the Investigator (INV-PFS)

Time from randomization to first documented disease progression assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first. Tumor assessments use Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Assessments are performed every 6 weeks through Week 54 and every 9 weeks thereafter.

Time frame: From randomization to disease progression or death, whichever occurs first; assessed up to 24 months.

Objective Response Rate Assessed by BICR (ORR)

Percentage of randomized participants whose best overall response is complete response (CR) or partial response (PR). Responses and progression are assessed by blinded independent central review (BICR) per RECIST v1.1.

Time frame: From randomization to the end of tumor assessment follow-up; assessed up to 24 months.

Objective Response Rate Assessed by the Investigator (ORR)

Percentage of randomized participants whose best overall response is complete response (CR) or partial response (PR). Responses and progression are assessed by the investigator per RECIST v1.1.

Time frame: From randomization to the end of tumor assessment follow-up; assessed up to 24 months.

Disease Control Rate Assessed by BICR (DCR)

Percentage of randomized participants whose best overall response is complete response (CR), partial response (PR), or stable disease (SD). Responses and progression are assessed by blinded independent central review (BICR) per RECIST v1.1.

Time frame: From randomization to the end of tumor assessment follow-up; assessed up to 24 months.

Disease Control Rate Assessed by the Investigator (DCR)

Time frame: From randomization to the end of tumor assessment follow-up; assessed up to 24 months.

Duration of Response Assessed by BICR (DoR)

Time from the first documented complete response (CR) or partial response (PR) to first documented disease progression or death from any cause, whichever occurs first, among responders. Responses and progression are assessed by blinded independent central review (BICR) per RECIST v1.1.

Time frame: From first complete or partial response to progression or death, whichever occurs first; assessed up to 24 months.

Duration of Response Assessed by the Investigator (DoR)

Time frame: From first complete or partial response to progression or death, whichever occurs first; assessed up to 24 months.

Number of Participants With Adverse Events

Adverse events (AEs) are summarized by incidence, severity, and outcome. Severity is graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0.

Time frame: From informed consent through 90 days after the last dose or initiation of new anticancer therapy, whichever occurs first; Up to 28 months.

Number of Participants With Serious adverse events (SAEs)

Serious adverse events (SAEs) are summarized by incidence, severity, and outcome. Severity is graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0.

Time frame: From informed consent through 90 days after the last dose or initiation of new anticancer therapy, whichever occurs first; Up to 28 months.

Number of Participants With Immune-related AEs

Immune-related AEs are summarized by incidence, severity, and outcome. Severity is graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0.

Time frame: From informed consent through 90 days after the last dose or initiation of new anticancer therapy, whichever occurs first; Up to 28 months.

JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer

Overview

Conditions

Interventions

Eligibility

Locations (2)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts